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The increasing incidence and prevalence of antibiotic resistance in bacteria threatens the
“antibiotic miracle.” Conventional antimicrobial drug development has failed to replace the
armamentarium needed to combat this problem, and novel solutions are urgently required.
Here we review both natural and synthetic RNA silencing and its potential to provide new
antibacterials through improved target selection, evaluation, and screening. Furthermore,
we focus on synthetic RNA silencers as a novel class of antibacterials and review their
unique properties.
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NATURAL RNA SILENCING IN BACTERIA
RNA silencing is widespread in nature. The transcripts involved
are often termed non-coding regulatory RNAs or antisense RNA,
and there are a range of mechanisms and cellular roles described
(Thomason and Storz, 2010). These natural examples of RNA
silencing provide important information about how synthetic
RNA strategies can be best developed in practice.
RNA-SILENCING MECHANISMS
In bacteria, there are fascinating examples of trans- and cis-
antisense sequences that reversibly repress translation. The reg-
ulatory regions within a single mRNA can contain neighboring
cis-antisense sequences that form an intra-molecular antisense–
sense fold. The folded structure masks or sequesters the ribosome-
binding site (RBS), and this prevents initiation. Although, this
arrangement is less obvious as a mechanism for antisense control,
it was ﬁrst described as early as 1985, and has now been associated
with the regulation of many genes. Also, cis-antisense sequences
may arise from transcription from the complementary strand at
the same locus, and it is now clear that occur as frequently in sim-
ple unicellular bacteria as they do in higher organisms (Georg and
Hess, 2011). Many natural antisense sequences are trans-acting
regulatory RNAs, where the antisense RNA is transcribed from a
distant locus. There may be a bias toward the discovery of such
trans-encoded RNAs, as this is the anticipated nature of antisense;
however, it seems likely that this is a common mechanism for nat-
ural antisense. In prokaryotes, trans-encoded antisense sequences
typically work by binding to the start codon region of mRNA.
For example, MicF RNA represses the translation of the outer
membrane protein gene ompF (Delihas and Forst, 2001), and the
OxyS RNA inhibits translation of two target genes, fhlA and rpoS
(Altuvia et al., 1998). There are diverse examples of RNA silencing
in bacteria (Thomason and Storz, 2010; Georg and Hess, 2011).
Antisense sequences that hybridize to messenger RNA can
inhibit target gene expression in several ways; reviewed in-depth
in Waters and Storz (2009). Perhaps the simplest mechanism is
translation repression. It is easy to envision how this can occur
in bacteria, where the ribosome binds to mRNA at the well-
characterized RBS (Shine and Dalgarno, 1974). Blocking this
initiation process by the positioning of an antisense sequencing
at the RBS leads to unmasking of the messenger RNA and decay of
the unused transcript. Therefore, RNA-silencing involves a com-
bination of repression of initiation and transcript decay (Figure 1)
and natural antisense transcripts have additional conﬁrmed func-
tional roles in transcription termination, co-degradation, tran-
scriptional interference, and enhanced stability of their respective
target transcripts. Furthermore, the recently described clustered
regularly inter-spaced short palindromic repeats (CRISPR) mech-
anism provides acquired resistance against bacteriophage and
involves RNA-mediated destruction of phage transcripts (Horvath
and Barrangou, 2010). Therefore, there are a wide range of natural
antisense mechanisms and functional roles, pointing the way to a
variety of opportunities for synthetic RNA-silencing tools.
ANTISENSE RNAs ENCODED IN BACTERIAL CHROMOSOMES AND
PLASMIDS
The ﬁrst natural antisense mechanisms identiﬁed were associated
with accessory elements in bacteria and viewed as peculiarities
within the area of gene expression control. It is now clear that anti-
sense mechanisms are abundant, widespread, and involved in core
cellular processes as well as adaptive responses. Therefore, RNA
silencing is a common and important form of posttranscriptional
gene control.
STRUCTURAL FEATURES OF SHORT ANTISENSE RNAs AND TARGET
BINDING
Two typical features of ncRNAs in bacteria are a short length and
a stable secondary structure. A folded structure can contribute
nuclease resistance and distinct functional domains (Majdalani
et al., 1998). Also, the structure itself may aid recognition and
www.frontiersin.org September 2011 | Volume 2 | Article 185 | 1
Good and Stach Synthetic RNA silencing
FIGURE 1 | Natural RNA silencing in bacteria. (A) Antisense
RNAs (asRNAs) that are cis-encoded share high degrees of
complementarity with the target mRNA. (B) asRNAs that are
trans-encoded have limited complementarity with the target mRNA
and, in some species, require the an RNA chaperone (Hfq) to
facilitate binding. In either case, once the asRNA is bound to the
target mRNA, translation of the target gene (tarX) is silenced by
inhibition of ribosome binding to the target mRNA (i); induced
RNase degradation of the asRNA:mRNA hybrid (ii) or a combination
of both processes.
binding. Folding may improve target binding through rapid loop–
loop interactions. Among bacterial antisense RNAs, comparative
sequence analysis revealed the “U-turn” structure, which consists
of a short hairpin with a tetra-loop containing the YUNR motif
(pyrimidine, uracil, any nucleoside, purine). This is an example of
a motif that aids antisense interactions (Franch et al., 1999).
PROTEIN FACTORS INVOLVED IN RNA SILENCING
Antisense RNAs have the capacity to work alone as gene regu-
lators through RNA/RNA interactions; however, protein factors
may also play a role by binding to antisense and target RNAs.
Double-stranded RNA binding domains are well known as factors
in RNA processing, and these domains may mediate RNA interac-
tions. Also, a eukaryotic Sm-like sequence motif is present in many
antisense RNAs, and the E. coli Sm homolog Hfq recognizes this
motif both within the antisense RNA and target mRNA, and Hfq
can stabilize an interaction (Møller et al., 2002a). Sm and Sm-like
proteins are involved in a number of RNA metabolism/processing
steps in eukaryotes, and this role is conserved in bacteria, where
Hfq mediates antisense–sense RNA pairing (Figure 1).
SEQUENCE-SELECTIVE RNA SILENCING
The problem of sequence-speciﬁc target recognition must be con-
sidered with an appreciation of transcript biology and complexity.
Simple sequence uniqueness calculations suggest that gene or
sequence-speciﬁc inhibitory effects in bacteria require a target
sequence of approximately 12 bases (Good et al., 2001),whereas in
mammalian cells 15 ormore bases are neededdue to larger genome
sizes. These estimates are supported by the structure and activity
of natural and synthetic antisense sequences; natural antisense
RNAs typically form 12–30 bp with target mRNA, but binding
is often complicated by the presence of mismatches and gapped
structures. Designed antisense agents range in size from 6 to 25
residues, and are often near 20 residues for mammalian cell appli-
cations. Therefore, antisense agents tend to be just long enough
to provide stable binding properties and gene-speciﬁc recogni-
tion. This is reasonable given that delivery is a major restriction.
Natural antisense RNAs are typically longer, but in some cases
only a portion of the transcript is involved in target hybridiza-
tion. The rate-limiting step in RNA/RNA interactions is sequence
recognition. Diffusion can be a factor particularly for large RNA
molecules; however, RNA/RNA hybridization appears to be inher-
ently constrained, possibly by electrostatic repulsion (Franch et al.,
1999). The U-turn motif described above provides one way to
reduce such constraints to binding. A prototype example of anti-
sense RNA/mRNA recognition and binding that involves U-turn
structures is the copA/copT system involved in plasmid replica-
tion control. Known as the “kissing-complex” interaction, hairpin
loop heads on both the antisense, and target sequence speed ini-
tial binding. Kissing loops provide a meta-stable interaction that
can extend to provide the binding stability needed to inhibit the
target RNA. Also mismatches between the copA/copT RNAs ease
loop extension and formation of the ﬁnal stable binding complex
(Kolb et al., 2000). Therefore, successful antisense interactions and
stabilized binding can depend on sequence composition, higher-
order structural motifs and in some cases complex RNA dynamics
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during binding. It may be possible to mimic some aspects of the
these fascinating, evolved mechanisms.
WHY DO BACTERIA USE ENDOGENOUS RNA SILENCING?
RNA structure and function has been described as having high
evolvability (Waters and Storz, 2009), and interactions between
RNAs can provide subtle and profound changes in biological
processes. Bacteria beneﬁt from these features and a range of
remarkable RNA-level regulatory processes have evolved. Some
of the best understood of these involve antisense repression of
translation. An important feature of translation repression is
that the mRNA can remain intact during periods of repression,
and rapid expression switching may occur in response to cel-
lular and environmental signals. Antibiotic exposure requires a
rapid response to ensure cell survival, and it seems reasonable for
cells to constitutively transcribe antibiotic resistance genes and
then control expression at the translation level. Cis-encoded anti-
sense sequences arewithin the chloramphenicol and erythromycin
resistance genes in E. coli (Moffat et al., 1994). For both the chlo-
ramphenicol and erythromycin resistance genes, rapid expression
control appears to be provided by antisense sequences that lie
within a short open reading frame just upstream of the start
codon region. Also, RNA-silencing appears to enable gene con-
trol within operons. For example, Spot 42 RNA repression of galK
at an internal position within the galETKM operon transcript
(Møller et al., 2002b) effectively discoordinating expression of an
otherwise coordinated expression system. Finally, RNA silencing is
involved in the bacterial CRISPR mechanism to guard against viral
infection. Therefore, phenotypes as diverse as antibiotics resis-
tance and phage resistance involve natural RNA silencing and
there are clear beneﬁts to the cell in involving RNA-level gene
control.
DIFFICULTIES IN THE PRACTICAL APPLICATION OF SYNTHETIC RNA
SILENCING IN BACTERIA
There are many potential research and practical applications
of RNA silencing. Examples from nature showing how bacteria
themselves utilize RNA::RNA interactions to regulate gene expres-
sion supports the notion that synthetic RNA silencing can be of
practical beneﬁt. This is particularly attractive for species where
standard genetics or conventional drug development has yet to
provide satisfactory solutions. Nevertheless, despite the promise
of the approach and the insight provided by nature, difﬁculties
remain in getting RNA silencing to work well in diverse practical
applications.
As described in detail below, there are two general strategies
to RNA silencing, where the silencing agent is either expressed
as a natural RNA transcript within cells (expressed asRNA) or
where the silencing agent is a short non-natural nucleobase poly-
mer that is delivered into bacteria. In both cases it is self evident
that the silencing sequence must be sufﬁciently abundant in cells
to sequester the bulk of transcript mRNA to effectively repress
translation initiation. To reach such levels, it is necessary to use
efﬁcient expression or delivery and stabilizing structures that limit
nuclease decay in cells.
In the case of expressed RNA, it is standard practice to use
strong and tightly inducible promoters. In addition, evidence
for rapid transcript decay in cells has led to effort to stabilize
asRNA following synthesis by including stabilizing RNA struc-
tures within the asRNA transcript. For example, the transcript
termini can be paired by introducing complimentary termini that
generate a stem structure that simultaneously protects both the
5′ and 3′ termini, resulting in an accumulation of PTasRNA in
cells, providing more effective silencing (Nakashima et al., 2006).
As expected, improved silencing correlated with transcript abun-
dance, conﬁrming that a challenge to effective RNA silencing is
to achieve sufﬁcient intracellular concentrations of the asRNA
sequence (Figure 2).
In the case of short non-natural nucleobase polymers, it is stan-
dard practice in antisense, and siRNA design to use stabilizing
nucleic acid analogs or mimics that resist decay by cellular nucle-
ases. For bacterial applications,we have focused on peptide nucleic
acid (PNA;Goodet al., 2001),where the sugar phosphate backbone
is entirely replaced by a pseudopeptide backbone, apparently pro-
viding full protection. Phosphorothioate morpholino oligomers
(PMOs) provide similar advantages, involving different chemistry
for full backbone replacement (Geller et al., 2003). Indeed, organic
chemists provide a variety of analogs and mimics that can poten-
tially act as stable and effective RNA silencers in bacteria. Perhaps
the larger challenge is to achieve sufﬁcient intracellular delivery
across stringent bacterial cell barriers. Nucleobase oligomers that
are long enough for sequence recognition are inherently too large
for uptake by simple diffusion. Fortunately, bacterial barriers can
be overcome by conjugating the oligomers (PNA or PMO) to cell
entry peptides, which are typically cationic (Nikravesh et al., 2007;
Mellbye et al., 2009). There are difﬁculties with developing such
peptides as components or drugs, and further developments are
needed, but the peptide conjugates that have been described to
date provide effective delivery in bacteria grown in culture and as
pathogens within animals.
In all applications of RNA silencing it is difﬁcult to design
silencers that speciﬁcally recognize and inhibit the target mRNA
without unintended effects. In the case of bacteria, the situa-
tion is somewhat easier, because bacterial genomes are relatively
small. Nevertheless, it is important to carefully design and eval-
uate silencers to ensure gene-speciﬁc effects. For expressed RNA,
we typically target 100–150 bases surrounding the RBS. For PNA,
we typically target a site of 10–15 bases in length, taking care
to cover the Shine–Dalgarno sequence or start codon within the
RBS region. Our design guidelines have been described previously,
along with a description of control experiments that are needed to
ensure gene selective silencing (Dryselius et al., 2003a). As controls
to ensure gene speciﬁcity, we favor phenotype complementation,
where the target gene is over expressed to rescue cells from the
affects of RNA silencing, thus conﬁrming the mechanism of action
(Goh et al., 2009).
SYNTHETIC RNA SILENCING FOR GENE FUNCTION STUDIES
AND ANTIMICROBIAL DISCOVERY
The use of synthetic RNA silencing has applications in the discov-
ery of novel antimicrobial targets, determination of the stringency
of requirement for those targets, the development of highly sen-
sitized antimicrobial screens, mode of action studies, and in the
growing ﬁeld of polypharmacology.
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FIGURE 2 | Abundance and stability of antisense RNA is related to the
efficacy of gene silencing. (A) Linear asRNAs are subject to degradation by
RNases (i) and thus, are not available to form hybrids with their target mRNA.
The role of Hfq in trans-encoded asRNAs with a high degree of sequence
complementarity with the target mRNA is not elucidated, however, as with
natural asRNAs, Hfq may serve to protect asRNAs from degradation (ii).
In situations where the abundance and stability of the linear asRNA is low,
only partial gene silencing will result (iii). (B) Addition of paired-termini to the
asRNA results in asRNAs that have increased abundance, likely as a result of
resistance to RNase degradation (iv). The role of Hfq in PTasRNA-mediated
gene silencing is unclear. The increased abundance of PTasRNAs results in a
higher level of gene silencing (v).
TARGETS
In the post-genomic era, the process of discovering novel antimi-
crobial compounds can be broadly described as: (i) identiﬁcation
of novel essential genes, (ii) development of novel, preferably
whole-cell, screens, and (iii) validation of the mode of action
(MOA) of antibacterial compounds (Thomson et al., 2004). RNA
silencing is applicable to each of these areas, and its use has resulted
in the discovery of potent andnovel antimicrobial compounds (see
below). The construction of artiﬁcial antisense RNA silencers, to
aid in the identiﬁcation of novel antimicrobial targets, can fol-
low random or targeted design strategies. The random approach
is exempliﬁed by the studies of Ji et al. (2001) and Forsyth et al.
(2002). In both studies, genomic DNA of Staphylococcus aureus
was shotgun fragmented (200–800 bp), blunt-ended, and cloned
into an inducible expression vector. Transformation of S. aureus
with the fragment library followed by phenotype comparison,
on inducing and non-inducing plates, revealed clones that had
growth defective or lethal phenotypes. Sequencing of these clones
revealed 70% to contain genome fragments in the antisense ori-
entation (Forsyth et al., 2002). An analysis of the binding sites of
the randomly generated RNA silencers showed them to be dis-
tributed across the length of their target genes. Interestingly, in
contrast to natural trans-encoded antisense RNAs (see above), the
authors noted that there was a notable absence of RNA silencers
that mapped to the N-terminal of the gene. They suggested that
there may be preferential target sites for antisense inhibitory activ-
ity or that RNA silencers targeting the N-terminus of the gene
were deleterious to the growth of E. coli (used to amplify the shot-
gun library prior to S. aureus transformation). The principal aim
of both of the above studies was the facile, unbiased identiﬁca-
tion of essential genes; a prerequisite for the development of novel
antimicrobial compounds. The adoption of a similar approach
in Gram-negative bacteria has yet to be published. The reason for
this is not clear, but may include different RNA chaperone require-
ments for trans-acting antisense RNAs (Waters and Storz, 2009);
in S. aureus Hfq is not required for functional regulatory RNAs
and lacks the C-terminal domain that binds to A-rich domains
of the target mRNA (Lorenz et al., 2010). Furthermore, a lower
abundance of the expressed antisense in Gram-negative bacte-
ria could be explain the different efﬁcacies in Gram-negative and
positive species: S. aureus lacks an RNAse E homolog, which may
explain the efﬁcacy of expressed antisense silencers in this species.
(Xu et al., 2010) noted that use of an E. coli RNAse E mutant
resulted in a signiﬁcant improvement in the frequency of isolation
of clones expressing antisense RNA that were complementary to
essential genes. The use of PTasRNA (see above) may also enable
shotgun-based approaches to be employed in the identiﬁcation of
essential targets in Gram-negative species. It remains to be deter-
mined whether Hfq is required for RNA silencing with PTasRNAs
(Figure 3).
TARGET STRINGENCY
The fact that a gene is essential is not necessarily a predictor of the
drugability of its cognate protein, i.e., inhibition of the essential
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FIGURE 3 | Measuring the degree of gene essentiality.The relationship
between the reduction of growth rate and the reduction in mRNA
(antisense-induced gene silencing) is a measure of the degree of
essentiality, or stringency, of an essential gene (Goh et al., 2009). The
minimum transcript level for a 50% reduction in growth (MTL50, dotted line)
can be used to compare genes. In this hypothetical example three genes
are compared and show low (white line), medium (gray), and high (black)
stringencies of requirement.
protein may not lead to arrested growth or cell death. Thus, the
identiﬁcation of targets that are stringently required (those that
cause signiﬁcant growth defects when subject to comparatively
low degrees of inhibition) is highly desirable. In order to assess
such target stringency at the protein level, speciﬁc inhibitors,
with known inhibition kinetics would be required for all essen-
tial proteins and is not currently feasible. However, a quantitative
measure of the stringency of requirement of essential genes can
be used for predictive purposes: Goh et al. (2009) hypothesized
that essential genes differ in requirement stringencies, and that
those differences could be revealed by measuring the relationship
between the decrease in a speciﬁc mRNA and bacterial growth
rate decline (Figure 3). In their study they selected four essen-
tial genes in E. coli (acpP, fabI, ftsZ, and murA) and applied
both expressed (PTasRNAs) and oligo-nucleobase (PNAs) RNA
silencers to selectively titrate down gene expression and measure
growth responses. The authors used a minimum transcript level
for a 50% reduction in growth rate (MTL50) to compare the four
genes and showed that the hierarchy of stringency had the order
acpP> ftsZ> fabI>murA. The results indicated that to maintain
50% viability E. coli requires >70% of the acpP transcripts rela-
tive to a normal cell, whereas only 40% of the murA transcripts
are required. Interestingly, MurA is the target of a clinically used
antimicrobial (fosfomycin), suggesting that AcpP may be an inter-
esting target for antimicrobial discovery; FtsZ has been the subject
of a number of antibacterial discovery programs (Lock and Harry,
2008). The assessment of the stringency of requirement may pre-
vent the selection of poor targets early in the discovery phase of
antimicrobial development.
SCREENING
Novel antimicrobial compounds are assessed for their ability to
inhibit growth (bacteriostatic) and kill (bacteriocidal) bacteria
in vitro. Currently, there is a lack of clinical data to support the
preferential development of either class of compounds, as clin-
ical outcomes are often overlooked in evaluation (Pankey and
Sabath, 2004). However, bacteriocidal properties are often sought
in antimicrobial development. In particular, bacteriocidal agents
are preferred in the treatment of slow growing organisms such
as Mycobacterium tuberculosis, where the majority of viable anti-
tubercular agents are bactericidal. (Kaur et al., 2009) showed that
conditional RNA silencing of an essential gene target at relatively
high cell number,with subsequentmonitoring of cell number over
time, can be applied to determine whether the inhibition of the
cognate essential protein is likely to result in bacteriostasis or bacte-
riocide (Figure 4). In their study, mycobacterial genes that encode
proteins that are the targets of standard anti-tubercular drugs
(inhA, rpoB, and gyrA)were shown to be bactericidal when subject
to RNA silencing, whereas silencing of ftsZ was bacteriostatic.
Once a target has been selected for antibacterial discovery, RNA
silencing can be applied to for the development of antibacterial
screens. In theory, a strain expressing antisense RNA, or exposed
to a nucleobase RNA silencer, targeting a speciﬁc mRNA, will
have a lower cellular pool of the cognate protein and thus will
become sensitized to inhibitors of that protein. RNA-silencing
based antimicrobial screens require that the expression of only
the target(s) of interest be knocked down; an RNA silencer may
target a single gene, or multiple genes via binding site similari-
ties or their presence in operons downstream of the target gene
(Dryselius et al., 2006). The speciﬁcity of RNA silencing has been
demonstrated by a number of methods including: Western blot
analysis of the target protein in induced and non-induced strains
(Ji et al., 2004); reversible knockdown of auxotrophy (Kaur et al.,
2009); complementation of the target gene (Dryselius et al., 2003b;
Goh et al., 2009); silencing of reporter genes (Nekhotiaeva et al.,
2004; Dryselius et al., 2006); and qRT-PCR (Dryselius et al., 2006;
Goh et al., 2009; Kaur et al., 2009). In addition, the utility of
expressed antisense RNA silencers in drug discovery was proven
by the fact that an S. aureus strain expressing an antisense RNA to
the gene fabF was 12-fold more sensitive to cerulenin (a speciﬁc
inhibitor of FabF) when RNA silencing was induced. In con-
trast, that same strain was not signiﬁcantly sensitized to other
antibiotics (Forsyth et al., 2002). Speciﬁcity has also been demon-
strated in E. coli where sensitization to triclosan (FabI inhibitor)
FIGURE 4 | Antisense prediction of bacteriostatic and bactericidal
targets. Antisense-induced silencing of essential genes and subsequent
monitoring of survival kinetics can be used to delineate targets that will
likely produce cidal, static, or no effect upon inhibition of the cognate
protein (adapted from Kaur et al., 2009).
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but not trimethoprim or rifampicin, was observed upon induc-
tion of antisense fabI RNA (Nakashima et al., 2006). Furthermore,
combination treatment of both E. coli and S. aureus with PNAs
and protein-level inhibitors only resulted in antimicrobial synergy
when both compounds were directed to the same target (Dryselius
et al., 2005), indicating that nucleobase RNA silencers have sim-
ilar target speciﬁcity. The use of RNA silencing for antimicrobial
screening has a particular advantage when screening natural prod-
uct extracts; bioactive secondarymetabolites are often produced in
very small quantities (Olano et al., 2008). Thus, the increased sen-
sitization of the RNA-silencing based screens enables detection of
compounds that would be missed in standard whole-cell antimi-
crobial screens, or other target-directed whole-cell screens, such
as those where promoters of genes that are speciﬁcally upregu-
lated in response to antibacterial compounds with speciﬁc modes
of action are fused to reporter genes (Hutter et al., 2004). The
most convincing argument for the employment of RNA silenc-
ing in antibacterial screening has come from the discovery of
inhibitors of the fatty acid biosynthesis pathway. Merck Research
Laboratories used S. aureus strains expression antisense RNA to
fabF to screen 250,000 natural product extracts for FabF/FabH
inhibitors (fabF and fabH are organized in an operon). All known
natural product FabF and FabH inhibitors (cerulenin, thiolacto-
mycin, thiotetramycin, and Tü3010) were discovered using this
approach, in addition Phomallenic acids, new inhibitors of FabF
were discovered (Young et al., 2006). This discovery was followed
shortly after by the discovery of platensimycin a potent selective
inhibitor of FabF and platencin a similarly potent dual FabF/H
inhibitor (Wang et al., 2007). The fact that previous antimicrobial
screening of the same extract library had failed to identify these
compounds, a novel class of antimicrobials, is a convincing vindi-
cation of the use of RNA silencing in antimicrobial discovery. Use
of RNA-silencing based screens in Merck Research Laboratories
has also been demonstrated effective in the isolation of inhibitors
of rpsD (small ribosomal protein S4; Singh et al., 2008; Zhang
et al., 2009).
MODE OF ACTION
The identiﬁcation of a MOA is an important step in the devel-
opment of antibacterial compounds, not least to avoid rediscov-
ery of known molecules, but to deselect compounds that kill
through non-selective mechanisms. Furthermore, the elucidation
of a MOA can be used to determine if chemical modiﬁcations of
a lead structure result in compounds that retain the MOA of the
parent (Haydon et al., 2008) The fact that RNA-silencing based
antimicrobial screens are speciﬁcally sensitized for inhibition of
a known target, can be exploited to identify the MOA for known
antimicrobial compounds. A recent example was the proof that
berberine, a plant alkaloid used as an anti-infective in traditional
medicine,was an inhibitor of bacterial cell division (Boberek et al.,
2010). Domadia et al. (2008) had reported that berberine was a
likely inhibitor of FtsZ; data supporting this hypothesis included
NMR spectroscopy, FtsZ polymerization and GTPase assays, and
the observation of cell ﬁlamentation in E. coli cells treated with
berberine. However, cell ﬁlamentation in E. coli can result from
induction of the SOS response (SulA binds to FtsZ to prevent
cell division). Boberek et al. (2010) used RNA silencing in both
wild-type and sulA deletion strains of E. coli and showed that
berberine was indeed an inhibitor of cell division. While, RNA-
silencing studies of this nature are proven in the discovery of
antimicrobial compounds and their MOA, they have the draw-
back that only one target is screened at a time. In response to this
limitation, arrays of strains can be used to provide comprehensive
target coverage combined with accurate and facile determination
of MOA (Xu et al., 2010). For antimicrobial discovery, the gen-
eral approach of using a population of cells composed of strains
that have an individual deﬁciency for a speciﬁc protein was ﬁrst
demonstrated in fungal species, where deletion of one allele in a
diploid strain results in haploid insufﬁciency (HI) that can result
in lower ﬁtness relative to the parent strain (Giaever et al., 2002).
Strains that are HI for the gene target of an antifungal are thus
hypersensitized to inhibition. (Xu et al., 2007) used a population
of HI Candida albicans strains that were genetically barcoded so
that population shifts resulting from antifungal treatment could
be observed using microarray analysis; HI strains conferring both
hypersensitivity and resistance to the test antifungal could be
simultaneously identiﬁed. Such a ﬁtness test was applied in the dis-
covery of the parnafungins, a novel class of antifungal that inhibit
mRNA polyadenylation (Bills et al., 2009). The use of an equiv-
alent ﬁtness tests in S. aureus has recently been described, where
the use of RNA silencing was used to create the conditional alleles
of essential genes – termed the S. aureus TargetArray (Xu et al.,
2010). In the study, 236 RNA-silencing clones were produced to
knockdown expression of cognate targets. Pools of the strains were
subject to ﬁtness tests in the presence and absence of antibacterial
compounds, with strain responses measured by multiplex PCR.
The TargetArray methodology has been has been validated by the
elucidation of the MOA of protein synthesis and peptidoglycan
inhibitors (Donald et al., 2009; Huber et al., 2009).
POLYPHARMACOLOGY
Polypharmacology describes the phenomenon that a single com-
pound can bind speciﬁcally to two or more targets. As noted
above, antibacterial discovery in the post-genomic era has focused
on a model of development from single targets. However, this
model has failed to live-up to its initial promise. Reasons for
this failure are multifaceted, but include the observation that, for
single-target inhibitors, individual point mutations in the target
gene may be sufﬁcient to overcome inhibition (Yeh et al., 2009).
Furthermore, identiﬁcation of targets based on the deletion of
individual genes, and assessment of in vitro viability, may over-
look targets that are essential in vivo. Network analysis predictions
have highlighted the importance of perturbing multiple proteins
in order to overcome the limitations of single-target inhibitors
(Hopkins, 2008). The polypharmacological approach to antimi-
crobial development is validated by the fact thatmost of the targets
of successful (i.e., those in clinical use) antimicrobials are rarely
encoded by a single gene (Brötz-Oesterhelt and Brunner, 2008).
Thus, the development of screens that can identify combinations
of targets that can be inhibited by one compound are required
to identify novel antimicrobials with low resistance rates. Sensi-
tized antimicrobial screens are well suited for the development
of screens for polypharmacological antimicrobials, as bacteria are
known to use single antisense RNAs to regulate multiple genes (see
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above). Furthermore,multiple antisense RNAs can be expressed in
a single host (Nakashima and Tamura, 2009). Synthetic antisense
methods could be applied to the identiﬁcation of combinations
of known essential genes that display synergistic properties when
simultaneously silenced (dual essential), or combinations of genes
that are not essential when individually silenced, but are essen-
tial in combination (synthetic lethals). A systematic approach to
constructing antisense strains for all of the combinations of essen-
tial genes in a bacterium would be an insuperable task (In E.
coli >83,000 strains for two-pair constructs alone). However, the
process could be rationalized and focused by an understanding
of the antimicrobial interaction network (Figure 5). Such analy-
sis has revealed that antimicrobial drugs can be separated into
classes such that any two will interact purely synergistically or
purely antagonistically (Yeh et al., 2009). Thus antisense strains
could be constructed that silence combinations of genes in classes
known to have synergistic interactions. A random approach for
the identiﬁcation of synthetic lethals could be achieved by using
the shotgun cloning method in strains carrying deletions of non-
essential genes, for example, the Keio collection of single-gene
knockouts in E. coli (Baba et al., 2006). Cloning of the shot-
gun fragments into a mixture of the Keio strains, selection of
clones that show growth defects when the antisense is induced,
and sequencing of clones, could identify those that carry antisense
fragments to non-essential genes that are synthetically lethal in
combination with the individual gene knockout carried by the
host strain. Oligo-nucleobase RNA silencers have promise in the
area of polypharmacology, either as tools to identify and evaluate
targets (as above) or as polypharmacological antibacterials them-
selves. As with expressed RNA silencers, oligo-nucleobase silencers
can be applied in combination. To our knowledge, a study specif-
ically demonstrating antimicrobial synergy using multiple PNAs
FIGURE 5 | Functional classification of antimicrobial drugs by their
pairwise interactions. Adapted form (Yeh et al., 2006). Synergistic (red)
and antagonistic (green) interactions are highlighted. Circle size of the drug
classes represents the number of compounds examined and the line
thickness the number of interactions. The larger ellipses show higher-level
functional classiﬁcation of DNA synthesis inhibitors (orange) and protein
synthesis inhibitors of the 50S ribosome subunit. Selection of gene targets
from classes known to have synergistic inhibition properties could aid in the
selection of genes for the design of antisense-based screens for
polypharmacological targets and inhibitors.
has yet to be undertaken, but it would seem logical to use the
drug interaction network to identify novel gene targets that would
likely yield antimicrobial synergy. In our labs we have observed
that closely related species show different sensitivity to the same
antimicrobial PNA, preliminary bioinformatic studies have indi-
cated that this may be due to silencing of more than one essential
gene; evidence of polypharmacology (unpublished). This is to be
expected as the target site for PNAs is constrained (see above),
and offers a means to speciﬁcally design single PNAs that silence
multiple essential genes. Thus, synthetic gene silencing applied sin-
gularly, or in combination with chemical inhibition approaches,
represents a powerful tool in the search for polypharmacological
antimicrobial targets and drugs.
ANTISENSE ANTIBACTERIALS
Synthetic RNA silencers, such as PNAs and PMOs, are not only
valuable research tools in the discovery of novel antibacterial com-
pounds, but are themselves a novel class of antibacterial; use of
both the above compounds as antibacterials is well documented
(Good and Nielsen, 1998; Good et al., 2001; Eriksson et al., 2002;
Dryselius et al., 2003b; Nekhotiaeva et al., 2004; Tan et al., 2005;
Nikravesh et al., 2007; Mellbye et al., 2009). In this section we
focus on the unique properties of these compounds and the likely
beneﬁts to antimicrobial development.
SPECIES-SPECIFIC ANTIMICROBIAL COMPOUNDS
Economic and diagnostic pressures have traditionally favored the
development of broad-spectrum antibiotics (Casadevall, 2009);
these drugs have enabled empirical usage (i.e., without the use
of diagnostic identiﬁcation of the pathogen) and rapid treat-
ment of life-threatening infections. However, the development
of resistance to broad-spectrum antibiotics is, in part, a con-
sequence of their indiscriminate MOA. The vast majority of
bacteria on and within the human body (the microﬂora) are
non-pathogenic, with many being beneﬁcial to health (Eckburg
et al., 2005). Broad-spectrum antibiotics that kill or suppress the
growth of these species can have negative outcomes in patient
treatment as a result of secondary infection following disrup-
tion of the resident microﬂora (Fowler et al., 2007; Casadevall,
2009) or through the selection of resistance mechanisms in non-
target species that are passed, by horizontal transfer, to pathogenic
species. Furthermore, the microﬂora are associated with devel-
opment and maturation of the immune system; perturbation
of this interaction, through the use of broad-spectrum antibi-
otics, has been implicated in increased risk of diseases such as
asthma, eczema, rhinoconjunctivitis, and breast cancer (Foliaki
et al., 2009). The degree of microﬂora perturbation associated
with broad-spectrum antimicrobials was highlighted in a recent
study by Jakobsson et al. (2010). In their study, the affect of
clarithromycin and metronidazole (used in the treatment of Heli-
cobacter pylori) on the microﬂora was investigated. The authors
observed dramatic shifts in the microﬂora of treated individu-
als, compared with the relatively stable populations of untreated
controls. A striking ﬁnding from this study was the observation
that, in some cases, the microﬂora perturbation remained for up
to 4 years post-treatment associated with an increased level of the
macrolide resistance gene erm(B). Narrow-spectrum (genus- or
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species-speciﬁc) antimicrobial agents, that are only active against
the causative pathogen could potentially overcome some of the
drawbacks of broad-spectrum antibiotic use, by ameliorating the
impact on non-target microﬂora. Theoretically, RNA-silencing
agents such as PNAs and PMOs have the greatest potential to
have a tailored spectrum of activity, as the degeneracy of the
genetic code ensures that there is greater variation at the genetic,
rather than phenotypic level. We have exploited the bactericidal
and sequence-speciﬁc properties of peptide-PNA conjugants to
design species-speciﬁc antimicrobial compounds that are capa-
ble of discriminating between closely related bacteria such as E.
coli, S. enterica, and K. pneumoniae in mixed culture (unpub-
lished). Such selectivity was not possible with single or mixed
application of known antibiotics. Furthermore, bioinformatic
comparison of E. coli and S. enterica revealed >100 target sites
for potential species-discriminating PNAs. We predict that it is
unlikely that a similar number of species-discriminating pheno-
typic targets could be identiﬁed for these closely related species.
The development and clinical implementation of species-speciﬁc
antimicrobials alongside immunotherapy approaches aimed at
improving host responses, is predicted to be the Third Age of
antimicrobial therapy (Casadevall, 2006, 2009; Then and Sahl,
2010) the unique MOA of bactericidal RNA-silencing compounds
make them good candidates for the development of narrow-
spectrum antibiotics. A further beneﬁt of the MOA of RNA
silencers, is their potential to overcome antibacterial resistance
(see below).
DELIVERY OF RNA SILENCERS AT SITES OF INFECTION
Efforts to develop RNA silencers as antimicrobials can be criticized
on the basis that nucleobase oligomers are considered to be inher-
ently too large to achieve efﬁcient cell uptake and in vivo distrib-
ution. However, peptide-PNA and peptide-PMO oligomer-based
antimicrobials perform well in cell kill assays in vitro and in vivo.
Also, there is renewed interest from clinicians in the efﬁcacy of
larger molecular weight antimicrobials (Falagas and Michalopou-
los, 2006). Nevertheless, restricted cell uptake of oligomer-based
antibiotics is an obvious difﬁculty. On the other hand, whereas
conventional antibiotics are rapidly expelled from bacteria by
efﬂux pumps (George and Hall, 2002), PNAs are retained for
several hours, and not removed by efﬂux pumps. This leads to
accumulation in cells and a long post-antibiotic effect (Nikravesh
et al., 2007). Such properties help to explain the potent bacte-
ricidal effects observed in vitro and in vivo. Whereas delivery of
antisense agents into bacteria remains a signiﬁcant challenge, once
delivered, the molecule is surprisingly well retained. These accu-
mulation and retention properties may prove particularly appro-
priate in new strategies for treating persistent, dormant, or drug
resistant infections. Therefore, if drug delivery can be achieved
at the site of infection, these antibiotics appear more likely to be
retained within pathogens and at the site of infection. Strategies
to improve delivery include altered oligomer chemistry, conjuga-
tion to carrier molecules, and encapsulation within nanoparticles.
To date, most progress has been made by conjugation to carrier
peptides; however, each of these areas is complex and researchers
are only beginning to explore the various opportunities available
to enhance uptake.
CAN WE SILENCE ANTIMICROBIAL RESISTANCE IN CLINICAL
APPLICATIONS?
Acquired antimicrobial resistance is typically conferred by expres-
sion of one or just a few genes. Therefore, in principle, it should be
possible to silence resistance to regain near full potency. Protein-
level inhibitors of beta-lactamase enzymes have helped to recover
the activity of beta-lactamase antibiotics. Unfortunately, it has
proven difﬁcult to extend this idea to other enzymes involved
in resistance, which has led to interest in the idea of silenc-
ing resistance genes at the mRNA level. Several in vitro studies
have demonstrated similar recovery of drug activity by silencing
resistance genes at the RNA level (Table 1). Development of the
approach for clinical applications would require that the RNA-
silencing agents satisﬁes all requirements as a drug and also works
well in combination with the partner antibiotic in vivo.
CONCLUSION
The requirement for novel antimicrobial compounds and strate-
gies is of upmost importance if we are to continue to reap
the beneﬁts of the antibiotic era; improved life expectancy and
Table 1 | Examples of RNA silencing of antibiotic resistance mechanisms using oligomers.
Species Antimicrobial
resistance gene
Oligomer
structure*
Drug(s) potentiated by
silencing of resistance
Reference
Escherichia coli Beta-lactamase (bla) PNA Ampicillin Good and Nielsen (1998)
chloromycetin acetyl transferase (cat ) EGS-DNA Chloromycetin Gao et al. (2005)
Multiple antibiotic resistance operon (mar) PS-DNA Norﬂoxacin White et al. (1997)
AcrB ODN Ampicillin Li et al. (2011)
AAC(6′)-I-type acetyltransferases [aac(6′)-Ib] EGS-LNA–DNA Amikacin Soler Bistué et al. (2009)
Pseudomonas
aeruginosa
Multi-drug efﬂux operon (oprM) PS-DNA Piperacillin, cefoperazone,
ciproﬂoxacin, levoﬂoxacin,
imipenem, and amikacin
Wang et al. (2010)
Pseudomonas putida npt ODN Kanamycin Morse et al. (2010)
Campylobacter jejuni CmeABC PNA Ciproﬂoxacin and erythromycin Jeon and Zhang (2009)
*PNA, peptide nucleic acid; EGS, external guide sequence; PS, phosphorothioate; ODN, oligodeoxynucleotide; LNA, locked nucleic acid.
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outcomes. The current dearth of truly novel antimicrobials in the
development pipelines requires that we explore multiple research
avenues in antimicrobial research. Synthetic RNA-silencing offers
several beneﬁts to antimicrobial research, indeed its use has already
aided in the discovery of novel antibacterial targets and com-
pounds and the future application of RNA silencing will, no
doubt, continue to realize novel antibacterials. Future priorities
for expressed RNA silencers include: Determination of target
stringency for known essential genes in a number of Gram-
negative and positive species, with correlation of data to known
antibacterial targets, and implementation of S. aureus TargetAr-
ray technology for a broad range of pathogenic bacteria. The
latter will likely require development of host strains based on
detailed understanding of the fate of expressed RNAs. The poten-
tial for oligo-nucleobase RNA silencers such as PNAs and PMOs
may require the development of second-generation carrier strate-
gies, possibly involving non-biological solutions. Investigation of
PNA antimicrobial efﬁcacy with leaky mutants of E. coli, sug-
gest that very signiﬁcant improvement could be made upon
improved delivery. Furthermore, a range of carrier molecules may
aid in target delivery to sights of infection, or to speciﬁc species.
The development of polypharmacological oligo-nucleobase RNA
silencers will also improve antibacterial efﬁcacy. Such improve-
ments could accelerate clinical evaluation of RNA silencers and
hopefully deliver a new class of antimicrobial compound with
unique design properties.
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